Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Year-End Report January – December 2023

A STRONG END TO A STRONG YEARFinancial development fourth quarter 2023 · Net sales increased by 12% to SEK 353 million (315). · The gross margin was 48.2% (45.8). · Adjusted EBITDA amounted to SEK 59.8 million (43.4), equivalent to an adjusted operating margin of 17.0% (13.8). · Operating profit (EBIT) amounted to SEK 41.4 million (31.5), corresponding to an operating margin of 11.7% (10.0). · Order intake increased by 51% to SEK 408 million (271). · Operating cash flow amounted to SEK 26.2 million (-49.3). Financial development January - December 2023 · Net

Sivers Semiconductors Reports Record Fourth-Quarter and Fiscal-Year 2023 Results

A record-breaking year and quarter, leads to profitability in Q4, 2023·Fourth-quarter revenue was SEK 73.882 million, up 48% year-over-year (YoY). ·Full-year revenue was SEK 236.334 million, up 78% year-over-year (YoY).  ·Adjusted EBITDA totaled SEK 21.032 million (–16.943). ·Company is finalizing a SEK 50 million loan facility extension with existing lenders; thus eliminating the need for capital contributions from shareholders. Kista, Sweden // Feb. 8, 2024 // Sivers  Semiconductors AB (STO: SIVE) Fourth quarter October-December 2023 · Net sales amounted

Polygiene Group invites you to a presentation of the fourth quarter 2023

Polygiene Group will publish its quarterly report for the fourth quarter (October-December) on February 15, 2024, at 8.00 CET. In connection to the announcement, Polygiene Group invites you to a video conference on the same day at 10.00 CET.· Presentation of the quarterly report, CEO Ulrika Björk · Review of the financial results, CFO Niklas Blomstedt The conference is expected to last 45 minutes and will be held in English.         Registration is made via the link below no later than February 14, 2024. Instructions regarding access to the conference will be sent out via e-mail

Corem signs ten-year lease for 5,160 sq.m. with SOS International in Copenhagen

Corem has signed a ten-year lease agreement with SOS International regarding 5,160 sq.m. of office space in Fairway House, Copenhagen. Move-in is planned for early September 2024. The office, which is on three floors, will be adapted to best respond to SOS International's needs and requirements, with detailed interior designing in collaboration with the tenant. "We have been looking for the right premises for our new headquarters for a long time and we have found it in Fairway House, where, in addition to a central location, we get a good working environment with high

Invitation – presentation of year-end report 2023

KlaraBo will publish its year-end report 2023 at 8:00 a.m. (CEST) on Thursday February 15, and will hold a webcast presentation and conference call at 09:00 a.m. (CEST) the same day. KlaraBo’s CEO Andreas Morfiadakis and Interim CFO Urban Ottosson will present the report and answer questions. The presentation will be held in Swedish. Conference call and webcast presentationTime: 09.00 a.m. (CEST) on Thursday February 15, 2024 Link to webcast below. Via the webcast you can ask questions in writing.Klarabo Year End Report 2023 (financialhearings.com) 

Fractal Gaming Group’s Year-end report, Q4, 2023

Fourth quarter 2023 · Net sales amounted to SEK 142.6 million (141.7). · Product profit amounted to SEK 58.2 million (52.4), with a product margin of 40.8% (37.0). · EBITDA amounted to SEK 12.6 million (13.3), corresponding to an EBITDA margin of 8.8% (9.4). · EBIT amounted to SEK 6.8 million (8.0), corresponding to an EBIT margin of 4.8% (5.7). · Operating cash flow amounted to SEK -56.2 million (15.0). · Interest-bearing net debt was SEK -7.9 million (115.6). · Earnings per share amounted to SEK 0.1 (0.1). · No items affecting comparability for the quarter.

Attendo’s year-end and Q4 report for 2023:SUCCESFUL TURNAROUND PROVIDES OPPORTUNITIES FOR NEW INITIATIVES

Attendo showed continued recovery in the last quarter of the last year with high growth and improved earnings. Overall sales increased with 17 percent and lease-adjusted operating result amounted to 151 MSEK (8). For the full year, this means a significantly improved financial position, with a stronger cash flow and a significantly reduced debt ratio. Attendo is thus well equipped to make strategic investments in the care of the future while resuming dividends to shareholders.Comments from Martin Tivéus, Attendo's CEO “In 2023, we have been able to show strong growth and a recovery in

Kela's main office is planned to undergo extensive renovation - Architects Davidsson Tarkela appointed as the architect and principal designer

Solwers Plc Press Release 08.02.2024 at 09:00 EEST The planning for the extensive renovation project of Kela's culturally significant main office has begun. The architectural and principal design responsibilities are entrusted to Architects Davidsson Tarkela Oy, a part of the Solwers companies. Designed by Aino and Alvar Aalto between 1953-1956, Kela's main office in Taka-Töölö, Helsinki, is in need of comprehensive renovation. Considered as one of the Aaltos' most successful buildings, this culturally significant complex pays attention to even the smallest details and material

Optomed’s Financial Statements Bulletin will be published on 15 February 2024

Optomed Plc Press Release 8 February 2024 at 9.00, Helsinki Optomed’s Financial Statements Bulletin will be published on 15 February 2024 Optomed will publish its Financial Statements Bulletin 2023 on 15 February 2023 approximately at 9.00 EET.   A telephone conference for analysts, investors and media will be arranged on the publishing day at 11.00 EET/10.00 CET. The event will be held in English. The presentation material will be available at www.optomed.com/investors 10.00 EET at the latest.   The participants are requested to register for the call in advance by email

Transcom Holding AB (publ): Invitation to Transcom’s Q4 2023 results presentation webcast

Transcom are pleased to invite you to their Q4 2023 financial update webcast on Thursday, February 22, at 9:00 am CET, following the release of Q4 2023 results at 8:00 am CET. The Q4 report and presentation will be available on https://www.transcom.com/global/about-us/investor-relations. Presentation details Date/Time: Thursday, February 22, at 9:00 am CET Online Registration link: https://app.livestorm.co/transcom-holding/transcom-holding-ab-q4-2023-results-presentation   Important note: Please register via the link above at least 5-10 minutes prior the webcast in order to

Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2023Fourth Quarter 2023 · Total revenue increased 14 per cent, 15 per cent at constant exchange rates, (CER)[ii], to SEK 6,844 M (5,991) · Haematology revenue increased 21 per cent at CER to SEK 3,640 M (3,025), driven by sales of Vonjo[®] of SEK 322 M, strong sales of SEK 1,323 M for Elocta[®], growth for Doptelet[®] excluding China of 59 per cent at CER and sales of Aspaveli[®]/Empaveli[®] of SEK 186 M · Immunology revenue increased 10 per cent at CER to SEK 2,905 M (2,643), driven by

Earnings upgrade - MindArk's net sales and profit after financial items increase significantly in Q4 2023

MindArk PE AB (publ) ("MindArk" or the "Company") expects to report results for the fourth quarter of 2023 that are higher than current market expectations. The Company estimates that net sales for the fourth quarter of 2023 will amount to approximately 45-47 MSEK. This represents an increase of approximately 55-61 percent compared to the same period last year. Operating profit for Q4 2023 is estimated to amount to approximately 25-27 MSEK, which corresponds to an increase of approximately 140-160 percent compared to the same period last year. Profit after financial items is estimated at

Transaction in Own Shares

    08 February 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |07/02/2024|+----------------------------------------------------------

Orexo Interim Report Q4 2023, incl. Full Year Report

Positive EBITDA in H2 setting the target for FY 2024 Q4 2023 highlights›     Total net revenues of SEK 166.0 m (156.1)›     EBITDA of SEK 12.4 m (-53.1), EBITDA excluding costs for legal processes and external non-­repeating ­­clinical trials, SEK 23.4 m (-0.1) ›     Net earnings of SEK -18.6 m (-91.8)›     US Pharma segment (Zubsolv® US) net revenues of SEK 151.3 m (142.6), in local currency USD 14.2 m (13.3), US Pharma EBIT of SEK 75.4 m (77.0)›     Cash flow from operating activities of SEK -2.6 m (-48.9), cash and invested funds of SEK 171.0 m (351.9)›     Earnings per

Targeted forest protection is in the interest of nature, forest owners and the forest industry

Safeguarding the biodiversity of forest nature requires, in addition to forest protection, the promotion of practices that strengthen the state of nature in commercial forests. Metsä Group has set a goal of verifiably strengthening the state of nature by 2030. "Forest protection and strengthening the state of nature in commercial forests support each other. It is important that the boundaries of protected areas and commercial forests become clearer than at the moment, as it also stabilizes the operating environment for wood procurement and forest ownership," says Ilkka Hämälä, President

Completed enrollment in the POSITANO study of CAM2029 in patients with polycystic liver disease

Lund, Sweden — 8 February 2024 — Camurus (NASDAQ STO: CAMX) today announces completed enrollment in the randomized, double-blind, placebo-controlled, multicenter Phase 2/3 study, POSITANO, evaluating the efficacy and safety of the company’s octreotide subcutaneous depot (CAM2029) in patients with symptomatic polycystic liver disease (PLD). PLD is a rare, genetic, and chronic disorder characterized by progressive growth of cysts in the liver, which can cause severe symptoms and result in impaired quality of life for patients. An estimated 37,000 patients in the US and EU are today living

Humana reports fourth quarter and full year 2023 results

Strong performance from the Group in 2023Fourth quarter, October–December 2023 · Net revenue was SEK 2,396 million (2,438), a decrease of 2 percent. · Organic growth was -2.5 percent (5.5). Organic growth excluding Personal Assistance was 7.8 percent (9.7). · Operating profit amounted to SEK 85m (127), a decrease of 33 percent. Adjusted operating profit amounted to SEK 89m (89). Adjusted operating profit excluding Personal Assistance amounted to SEK 78m (60), an increase of 30 percent. · Net profit after tax for the period amounted to SEK 8m (59). · Earnings per share

Bactiguard Holding AB’s year-end report 2023

Stable fourth quarter marking the end of a challenging yearFourth quarter 2023 (October – December) · Total revenues amounted to SEK 61.3 (72.2) million, a decrease of 15.0 %. Net sales amounted to SEK 56.3 (61.3) million. Adjusted for the currency effect, net sales decreased by 9 %. · Operating loss amounted to SEK 23.8 (13.3) million, a decrease of SEK 10.5 million. · EBITDA amounted to SEK -4.2 (-1.1) million. · Net loss for the period amounted to SEK 27.2 (14.2) million. · Loss per share, before and after dilution, amounted to SEK 0.78 (0.40). · Cash flow from

Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds

  Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds   VANCOUVER, British Columbia, 08 February 2024 (GLOBE NEWSWIRE) – Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a leading biotechnology company dedicated to transforming mental health and addiction treatment, proudly announces the issuance of two Notice of Allowances by the United States Patent and Trademark Office (USPTO) for compounds from the Company’s MYCO-005 and MYCO-006 families.

Strong result for Lantmännen – new record dividend to Swedish farmers

Lantmännen’s result for 2023, after net financial items and adjusted for items affecting comparability, amounted to 2 462 MSEK – a slight decline compared to the previous year’s record result of 2 536 MSEK.”Despite an unsettled geopolitical situation and a weaker economy, Lantmännen delivered a strong result for the full year of 2023. In particular, the Energy Sector, Swecon Business Area and our international businesses in Lantmännen Unibake reported very good results for the year, while the Swedish food operations had a much tougher time,” says Magnus Kagevik, Lantmännen’s Group President

AcadeMedia acquires Touhula in Finland

AcadeMedia has signed an agreement to acquire all shares in Touhula Päiväkodit. The acquisition includes 113 preschools with about 7,700 children in Finland and is in line with AcadeMedia’s strategy to grow internationally. Touhula had a turnover in 2023 of about EUR 100 million and EBIT of about EUR 3 million. The transaction is expected to be completed on March 1st, 2024. - For a long time we have seen Finland as an attractive country for Academedia and we are delighted to have found a good partner there, says Katarina Wilson, acting CEO of AcadeMedia. In the past few years, Touhula

Neste's Financial Statements Release 2023

Neste Corporation, Financial Statements Release, 8 February 2024 at 9 a.m. (EET) Strong end for the year, cash flow the highlight in 2023 Year 2023 in brief: · Comparable EBITDA totaled EUR 3,458 million (EUR 3,537 million) · EBITDA totaled EUR 2,548 million (EUR 3,048 million) · Cash flow before financing activities totaled EUR 751 million (EUR -390 million) · Comparable return on average capital employed (Comparable ROACE) was 23.9% over the last 12 months (30.1%) · Leverage ratio was 22.7% at the end of December (31 Dec 2022: 13.9%) · Comparable earnings per

Prostatype Genomics acquires CLIA Certificate to facilitate rapid US market launch with a significantly stronger financial outlook

Prostatype Genomics AB ("Prostatype Genomics" or "the Company") announces that its wholly-owned US subsidiary Prostatype Genomics Inc. has acquired a CLIA Certificate in its own name. Together with the announced CLIA laboratory agreement with Research Dx, this will enable the Company to enter the US prostate cancer market with its prognostic biomarker test Prostatype® upon accreditation from the CAP (College of American Pathologists) and formal technical validation of the Prostatype® test services. Prostatype Genomics expects to achieve these remaining steps and to initiate clinical use of

Outokumpu financial statement release 2023: Solid adjusted EBITDA in 2023 in a weaker stainless steel market

Outokumpu OyjFinancial statements releaseFebruary 8, 2024 at 9.00 am EETOutokumpu financial statement release 2023: Solid adjusted EBITDA in 2023 in a weaker stainless steel market Highlights in Q4 2023   •        Stainless steel deliveries were 450,000 tonnes (450,000 tonnes)*. •        Adjusted EBITDA amounted to EUR 72 million (EUR 110 million). •        EBITDA was EUR 15 million (EUR 103 million). •        ROCE amounted to -2.1% (22.6%). •        Operating cash flow was EUR 236 million (EUR 289 million incl. discontinued operations). •        Net debt amounted

There are no items matching the current filter
There are no more items matching the current filter
Back to top